Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LUYE PHARMA GROUP LTD.
绿叶制药集团有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

RENEWED INCLUSION OF THE GROUP'S INNOVATIVE ANTIDEPRESSANT RUOXINLIN® IN CHINA'S 2026 NATIONAL REIMBURSEMENT DRUG LIST

The board of directors (the "**Board**") of Luye Pharma Group Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") announces that Ruoxinlin® (toludesvenlafaxine hydrochloride sustained-release tablets), classified as a Class 1 innovative drug in China, has been successfully renewed in the 2026 edition of China's National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (the "**National Reimbursement Drug List**") for the treatment of major depressive disorder (the "**MDD**").

Depression is a common mental disorder in China that carries a high risk of recurrence and places a substantial burden on patients, their families and society. A nationwide epidemiological survey reported that the 12-month and lifetime prevalence rates of depressive disorders among adults in China were 3.6% and 6.8%, respectively.

Ruoxinlin® was approved for marketing in China in November 2022 and was included in the National Reimbursement Drug List for the first time in November 2024. It is China's first Class 1 innovative chemical drug for the treatment of MDD that is independently developed with proprietary intellectual property rights, marking the first breakthrough for locally developed innovative drugs in this therapeutic area. As a serotonin (5-HT), norepinephrine (NE), and dopamine (DA) reuptake inhibitor (the "**SNDRI**"), Ruoxinlin® provides comprehensive treatment for MDD with consistent efficacy. It significantly alleviates anxiety, retardation/fatigue and anhedonia, improves cognitive function, and helps restore social functioning. It also has a favorable safety and tolerability profile, without causing somnolence or adversely affecting sexual function, body weight or lipid metabolism.

In recognition of its clinical value, Ruoxinlin® is currently the only SNDRI antidepressant recommended as a first-line treatment in both the Chinese Guidelines for the Diagnosis and Treatment of Depressive Disorders (2025 Edition) and the Chinese Guidelines for the Prevention and Treatment of Depression in the Community. In addition, the new drug application for Ruoxinlin®'s additional indication of generalized anxiety disorder was accepted by the Center for Drug Evaluation of China's National Medical Products Administration in January 2026.

The Group believes that the successful renewal of Ruoxinlin®'s inclusion in the National Reimbursement Drug List will help continuously reduce patients' medication costs, further expand the product's market coverage and broaden its room for long-term growth. The central nervous system (the "**CNS**") is a therapeutic area in which the Group has a long-standing focus. The Group will continue to advance innovative research and development focused on unmet clinical needs, and to promote the global development and commercialization of innovative CNS medicines.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 15 November 2026

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.